The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.
 
Sawsan Rashdan
No Relationships to Disclose
 
Jessica N. Williams
No Relationships to Disclose
 
Penny Currykosky
No Relationships to Disclose
 
Farjana Fattah
No Relationships to Disclose
 
Jonathan Padro
No Relationships to Disclose
 
Katarzyna Wnuk-Lipinska
No Relationships to Disclose
 
Gro Gausdal
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Anthony Brown
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
David Micklem
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio
 
Robert J Holt
Employment - BerGenBio
 
James Lorens
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio
 
Murray Yule
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Samsung Bioepis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - ArQule (Inst); BerGenBio (Inst); ImClone Systems (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Bristol-Myers Squibb; Lilly; Lilly